Xilio Therapeutics (NASDAQ:XLO) Issues Earnings Results, Beats Expectations By $0.08 EPS

Xilio Therapeutics (NASDAQ:XLO) posted its earnings results on Tuesday. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.08, FiscalAI reports. The business had revenue of $12.65 million for the quarter, compared to analysts’ expectations of $8.52 million. Xilio Therapeutics had a negative net margin of 58.52% and a negative return on equity of 354.12%.

Xilio Therapeutics Stock Up 3.9%

XLO stock traded up $0.31 during trading on Thursday, reaching $8.07. 631,381 shares of the company’s stock were exchanged, compared to its average volume of 42,632. Xilio Therapeutics has a 1-year low of $6.47 and a 1-year high of $16.10. The firm has a market cap of $48.23 million, a PE ratio of -2.29 and a beta of -0.16. The company’s fifty day moving average price is $8.06 and its 200-day moving average price is $8.99.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on XLO shares. Weiss Ratings upgraded shares of Xilio Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 8th. Wall Street Zen upgraded Xilio Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, March 28th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $28.00.

Hedge Funds Weigh In On Xilio Therapeutics

Several hedge funds have recently modified their holdings of XLO. Jane Street Group LLC acquired a new stake in Xilio Therapeutics in the 4th quarter valued at about $27,000. Velan Capital Investment Management LP acquired a new stake in Xilio Therapeutics during the fourth quarter valued at approximately $109,000. State Street Corp lifted its stake in Xilio Therapeutics by 13.7% during the fourth quarter. State Street Corp now owns 186,390 shares of the company’s stock valued at $119,000 after purchasing an additional 22,500 shares during the last quarter. Squarepoint Ops LLC boosted its holdings in Xilio Therapeutics by 39.6% during the third quarter. Squarepoint Ops LLC now owns 328,794 shares of the company’s stock worth $277,000 after buying an additional 93,338 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Xilio Therapeutics by 68.3% during the fourth quarter. Renaissance Technologies LLC now owns 344,416 shares of the company’s stock worth $220,000 after buying an additional 139,716 shares in the last quarter. 54.29% of the stock is currently owned by institutional investors and hedge funds.

About Xilio Therapeutics

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.